NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DermTech, Inc. (OTC: DMTKQ) on behalf of long-term stockholders following a class action complaint that was filed against DermTech on October 15, 2023 with a Class Period from May 3, 2022 through November 3, 2022. Our investigation concerns whether the board of directors of DermTech have breached their fiduciary duties to the company. The com ...

DermTech notes that it doesn't have any intention to appeal the decision made by the Listing Qualifications Department. It also doesn't provide investors with details about what will happen to DMTK stock after the delisting. Investors on the lookout for more of the most recent stock market stories will want to stick around! On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article a ...

Loading... Loading... U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining around 0.1% on Tuesday. The Dow traded up 0.09% to 38,814.43 while the NASDAQ fell 0.01% to 17,855.89. The S&P 500 also rose, gaining, 0.19% to 5,483.50. Check This Out: Wall Street's Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 8% Dividend Yields Leading and Lagging Sectors Energy shares jumped by 0.7% on Tuesday. In trading on Tuesday, communication services shares fell by 0 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________ FORM 10-Q ________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38118 ________________________ DERMTECH, INC. (Exact Name of ...

Exhibit 99.1 • Cash, cash equivalents, restricted cash and short-term marketable securities were $42.4 million as of March 31, 2024. DERMTECH REPORTS FIRST-QUARTER 2024 FINANCIAL RESULTS -Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 24 percent year-over-year -Test revenue increased 7 percent versus the first quarter of 2023 SAN DIEGO – May 14, 2024 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomic ...

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California. The first research abstract, “ Non-invasive gene expression analyses to rule out melanoma in patients with Fitzpatrick skin types IV-VI” will be presented March ...

DermTech, Inc. (DMTK) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.93 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.70%. A quarter ago, it was expected that this company would post a loss of $0.68 per share when it actually produced a loss of $0.57, delivering a surprise of 16.18%.Over the last four quarters, the company has surpassed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________ FORM 10-K ____________________________________________________ x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware (State or other jurisdiction of incorporation or organization) 12340 El Camino Real, San Diego, CA Registrant's telephone number, including area code: (858) 450‑4222 Securities registered pursuant to Section 12(b) of the Act: | ...

Exhibit 99.1 DERMTECH REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS -Average selling price (ASP) for the DermTech Melanoma Test (DMT) increased 55 percent year-over-year -Test revenue increased 38 percent versus the fourth quarter of 2022 -Estimated cash runway into the first quarter of 2025 SAN DIEGO – February 29, 2024 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 finan ...

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2023 operating and financial results. In advance of the call on February 29, 2024, DermTech will issue its fourth-quarter 2023 earnings press release. For participants interested in asking questions ...